SCHEMBL4389353

SCHEMBL4389353

CCO[Si](OCC)(OCC)c1ccc(-c2ccccn2)nc1.CCO[Si](OCC)(OCC)c1ccc(-c2ccccn2)nc1.O[Fe]O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.41
LMNA P02545 4/20 0.41
P4HTM Q9NXG6 3/20 0.41
CYP1A2 P05177 2/20 0.41
CCR1 P32246 2/20 0.41
CCR5 P51681 2/20 0.41
CCR8 P51685 2/20 0.41
POLB P06746 1/20 0.41
METAP1 P53582 1/20 0.41
BLM P54132 1/20 0.41
HIF1A Q16665 1/20 0.41
DOHH Q9BU89 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
HTT P42858 3/20 0.41
TP53 P04637 2/20 0.41
ALOX15 P16050 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386223 0.95 KDM4E (0.45) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4383282 0.93 KDM4E (0.40) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4382217 0.93 LMNA (0.40) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4377427 0.93 LMNA (0.40) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4385997 0.93 KDM4E (0.42) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4385944 0.91 KDM4E (0.41) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4391990 0.91 KDM4E (0.41) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4390874 0.90 LMNA (0.40) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4388561 0.90 LMNA (0.40) KDM4ELMNAP4HTMCYP1A2CCR1
SCHEMBL4390883 0.90 LMNA (0.40) KDM4ELMNAP4HTMCYP1A2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084608-B2 2,2′ -bipyridine derivative having a reactive silyl group, its production method, and transition metal complex SHIN-ETSU CHEMICAL CO., LTD. (JP) 2011-12-27 US disclosed
US-20090299068-A1 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-12-03 US disclosed
EP-2128165-A1 2, 2´-bipyridine derivatives having reactive silyl group, production methods, transition metal complexes thereof Shin-Etsu Chemical Co., Ltd. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090299068-A1 2,2' -BIPYRIDINE DERIVATIVE HAVING A REACTIVE SILYL GROUP, ITS PRODUCTION METHOD, AND TRANSITION METAL COMPLEX CBR3, TST, HRH3 KDM4E 3085/4885LMNA 4659/4885P4HTM 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.